| Dr Doris Dawn Donald, MD | |
|
1000 1st St N, Alabaster, AL 35007-8703 | |
| (205) 650-8133 | |
| (205) 620-8889 |
| Full Name | Dr Doris Dawn Donald |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 1000 1st St N, Alabaster, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912953522 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 11072 (Alabama) | Primary |
| Entity Name | Jackson Hospital And Clinic, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073264107 PECOS PAC ID: 0547254153 Enrollment ID: O20040414000971 |
News Archive
Neovasc Inc., today announced the completion of patient enrollment in its COSIRA trial designed to further assess the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina.
Sequence gaps in human chromosome 15 have been closed by the application of 454 technology. Researchers writing in BioMed Central's open access journal Genome Biology have described a simple and scalable method for finishing non-structural gaps in genome assemblies.
BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.
A new test that examines large sections of the sentinel lymph node for genes expressed by breast cancer could reduce the risk of recurrence and multiple surgeries, doctors say.
› Verified 8 days ago
| Entity Name | Jackson Montgomery Emergency Physcians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952358590 PECOS PAC ID: 5597785634 Enrollment ID: O20051202000795 |
News Archive
Neovasc Inc., today announced the completion of patient enrollment in its COSIRA trial designed to further assess the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina.
Sequence gaps in human chromosome 15 have been closed by the application of 454 technology. Researchers writing in BioMed Central's open access journal Genome Biology have described a simple and scalable method for finishing non-structural gaps in genome assemblies.
BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.
A new test that examines large sections of the sentinel lymph node for genes expressed by breast cancer could reduce the risk of recurrence and multiple surgeries, doctors say.
› Verified 8 days ago
| Entity Name | Emergency Services Of Montgomery Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528310323 PECOS PAC ID: 6608028204 Enrollment ID: O20121205000519 |
News Archive
Neovasc Inc., today announced the completion of patient enrollment in its COSIRA trial designed to further assess the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina.
Sequence gaps in human chromosome 15 have been closed by the application of 454 technology. Researchers writing in BioMed Central's open access journal Genome Biology have described a simple and scalable method for finishing non-structural gaps in genome assemblies.
BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.
A new test that examines large sections of the sentinel lymph node for genes expressed by breast cancer could reduce the risk of recurrence and multiple surgeries, doctors say.
› Verified 8 days ago
| Entity Name | Nes Tennessee, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437606605 PECOS PAC ID: 3678472040 Enrollment ID: O20161031002328 |
News Archive
Neovasc Inc., today announced the completion of patient enrollment in its COSIRA trial designed to further assess the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina.
Sequence gaps in human chromosome 15 have been closed by the application of 454 technology. Researchers writing in BioMed Central's open access journal Genome Biology have described a simple and scalable method for finishing non-structural gaps in genome assemblies.
BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.
A new test that examines large sections of the sentinel lymph node for genes expressed by breast cancer could reduce the risk of recurrence and multiple surgeries, doctors say.
› Verified 8 days ago
| Entity Name | Integrated Care-alabama Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215572888 PECOS PAC ID: 8224462833 Enrollment ID: O20200107000485 |
News Archive
Neovasc Inc., today announced the completion of patient enrollment in its COSIRA trial designed to further assess the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina.
Sequence gaps in human chromosome 15 have been closed by the application of 454 technology. Researchers writing in BioMed Central's open access journal Genome Biology have described a simple and scalable method for finishing non-structural gaps in genome assemblies.
BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.
A new test that examines large sections of the sentinel lymph node for genes expressed by breast cancer could reduce the risk of recurrence and multiple surgeries, doctors say.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Doris Dawn Donald, MD 1200 Corporate Dr, Suite 230, Birmingham, AL 35242-2941 Ph: (205) 995-7980 | Dr Doris Dawn Donald, MD 1000 1st St N, Alabaster, AL 35007-8703 Ph: (205) 650-8133 |
News Archive
Neovasc Inc., today announced the completion of patient enrollment in its COSIRA trial designed to further assess the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina.
Sequence gaps in human chromosome 15 have been closed by the application of 454 technology. Researchers writing in BioMed Central's open access journal Genome Biology have described a simple and scalable method for finishing non-structural gaps in genome assemblies.
BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.
A new test that examines large sections of the sentinel lymph node for genes expressed by breast cancer could reduce the risk of recurrence and multiple surgeries, doctors say.
› Verified 8 days ago
Lloyd M Bridgers, M.D., Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8133 Fax: 205-620-8889 | |
Dr. Darrel Craig Weaver, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8133 Fax: 205-620-8889 | |
Omar Reago Billano, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8133 Fax: 205-620-8889 | |
Heinz Alexander Dueffer, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 1st St. North, Shelby Baptist Medical Center, Alabaster, AL 35007 Phone: 205-620-8188 | |
Dr. Richard Jason Smith, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 1st St N, Mail Slot 584, Alabaster, AL 35007 Phone: 501-686-8586 | |
Dr. Joseph Allen Tubbs, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8133 Fax: 205-620-8889 |